Clinical Trials Update provides you with latest news about clinical trials conducted by companies located in Medicon Valley and gives insight to progress in studies, results and possible indications. 

ALK-Abelló Announces Positive Third Year Results from Clinical Study with GRAZAX

1 March - ALK-Abelló announces positive results from the third treatment year of the GT-08 study with GRAZAX, the company's tablet-based vaccine against grass pollen allergy. The study documents that the highly significant clinical effect from the first and second years of treatment is sustained through the third year and even increases when taking into account the differences between the three pollen seasons. Furthermore, an increasing, positive effect on the immune system is documented.

Read more

Biovitrum and Syntonix Set to Begin Phase I/IIa Clinical Trial

4 March - The US Food and Drug Administration (FDA) have given Biovitrum AB (publ), Sweden, and Syntonix Pharmaceuticals, Inc., USA, approval for the initiation of a phase I/IIa safety and pharmacokinetic study of intravenous, long-acting, recombinant Factor IX (FIXFc) in previously treated hemophilia B patients. This first in human study aims to evaluate the safety and tolerability of FIXFc together with its pharmacokinetic profile (primarily its plasma half-life) after a single injection of six different doses. The study will be performed at two clinics in the United States.

Read more